Literature DB >> 10886057

Development of rotary blood pump technology: past, present, and future.

Y Nosé1, M Yoshikawa, S Murabayashi, T Takano.   

Abstract

Even though clinical acceptance of a nonpulsatile blood flow was demonstrated almost 45 years ago, the development of a nonpulsatile blood pump was completely ignored until 20 years ago. In 1979, the first author's group demonstrated that completely pulseless animals did not exhibit any abnormal physiology if 20% higher blood flows were provided to them. However, during the next 10 years (1979-1988), minimum efforts were provided for the development of a nonpulsatile, permanently implantable cardiac prosthesis. In 1989, the first author and his team at Baylor College of Medicine initiated a developmental strategy of various types of nonpulsatile rotary blood pumps, including a 2-day rotary blood pump for cardiopulmonary bypass application, a 2 week pump for ECMO and short-term circulatory assistance, a 2 year pump as a bridge to transplantation, and a permanently implantable cardiac prosthesis. Following the design and developmental strategy established in 1989, successful development of a 2-day pump (the Nikkiso-Fairway cardiopulmonary bypass pump) in 4 years (1989-1993), a 2 week pump (Kyocera gyro G1E3 pump) in 6 years (1992-1998), and a bridge to transplant pump (DeBakey LVAD-an axial flow blood pump) in 10 years (1988-1998) was made. Currently, a permanently implantable centrifugal blood pump development program is successfully completing its initial Phase 1 program of 5 years (1995-2000). Implantation exceeded 9 months without any negative findings. An additional 5 year Phase II program (2000-2005) is expected to complete such a device that will be clinically available.

Entities:  

Mesh:

Year:  2000        PMID: 10886057     DOI: 10.1046/j.1525-1594.2000.06634.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  2 in total

1.  Heart failure: Continuous-flow LVADs improve clinical outcomes.

Authors:  Yukihiko Nosé
Journal:  Nat Rev Cardiol       Date:  2010-04       Impact factor: 32.419

2.  First Turkish experience with the MicroMed DeBakey VAD.

Authors:  Deniz Suha Kucukaksu; Erol Sener; Akif Undar; George P Noon; Oguz Tasdemir
Journal:  Tex Heart Inst J       Date:  2003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.